phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide has been researched along with n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almada, RC; Biagioni, AF; Coimbra, NC; da Silva, JA; de Freitas, RL | 1 |
1 other study(ies) available for phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide and n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide
| Article | Year |
|---|---|
Panicolytic-like effects caused by substantia nigra pars reticulata pretreatment with low doses of endomorphin-1 and high doses of CTOP or the NOP receptors antagonist JTC-801 in male Rattus norvegicus.
Topics: Aminoquinolines; Analgesics, Opioid; Animals; Benzamides; Bicuculline; Dose-Response Relationship, Drug; Fear; gamma-Aminobutyric Acid; Male; Naloxone; Nociceptin; Nociceptin Receptor; Oligopeptides; Opioid Peptides; Pars Reticulata; Rats; Rats, Wistar; Receptors, Opioid; Somatostatin; Superior Colliculi | 2017 |